Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha

Peter McLaughlin, Elihu Estey, Armand Glassman, Jorge Romaguera, Felipe Samaniego, Ana Ayala, Kimberly Hayes, Anne Marie Maddox, H. Alejandro Preti, Fredrick B. Hagemeister

Research output: Contribution to journalArticlepeer-review

81 Scopus citations

Abstract

Treatment-related myelodysplasia (t-MDS) occurs less frequently with the nucleoside analogs than with DNA-damaging agents such as alkylators or topoisomerase II inhibitors. In a chemoimmunotherapy trial conducted between 1997 and 2003 in patients with stage IV indolent lymphoma, 202 patients were treated and 8 have developed MDS between 1 and 5 years after therapy, including 4 who received only fludarabine, mitoxantrone, and dexamethasone (FND) for 6 to 8 courses, with or without rituximab, followed by interferon alpha (IFN-α). Complex cytogenetic abnormalities were present in all patients. Abnormalities of chromosome 7 were present in 6 of the 8 patients, 3 of whom received only FND ± rituximab and IFN-α. The abnormalities of chromosome 7 were monosomy 7 in 4 patients (1 of which had add 7p in the remaining chromosome); 1 del 7q; and 1 der 7. MDS with features classically associated with DMA-damaging agents can occur following therapy with FND, with or without rituximab, and IFN-α.

Original languageEnglish (US)
Pages (from-to)4573-4575
Number of pages3
JournalBlood
Volume105
Issue number12
DOIs
StatePublished - Jun 15 2005

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint

Dive into the research topics of 'Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha'. Together they form a unique fingerprint.

Cite this